Dr M. Abubakr Shaikh The Aga Khan University Hospital, Karachi HEART FAILURE GUIDELINES: A COMPARISON.

Slides:

Advertisements

Similar presentations

© 2010, American Heart Association. All rights reserved. Evolving Patterns of Use and Appropriateness of Aldosterone Antagonists in Heart Failure Nancy.

Advertisements

EP Testing and Use of Devices in Heart Failure HFSA 2010 Recommendations.

Evaluation and Management of Acute Decompensated Heart Failure

Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with chronic systolic heart failure.

Cardiac Arrhythmia in Thalassaemia Limassol, 24 – 26 October 2012 Malcolm Walker University College and the Heart Hospitals, London Clinical Director Hatter.

Update on Indications for Cardiac Resynchronization Therapy Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate.

A Canadian View on Effective Use of VADS Value Based Care and the Role of INTERMACS in our Evolving Health Care Environment A Canadian View on Effective.

Clinical Trial Results. org Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction: A Meta-Analysis.

Syncope & serial troponins don’t mix Cost Containment Project June 2015 Alex Raufi PGY2.

Heart Failure Programs Europe and Belgium Sandra Martin Clinical Nurse Specialist UZ Leuven, Belgium.

Electronic Health Records and Clinical Decision Support Systems Impact on National Ambulatory Care Quality Max J. Romano, BA; Randall S. Stafford, MD,

Locally Agreed Guidelines May Reduce Inappropriate Preoperative Echocardiography Requests Dr Sheila Carey Anaesthetic SpR Northern Deanery.

Cardiac Resynchronization Therapy (CRT) Is an Effective Treatment for Heart Failure and Indications Are Expanding Multiple trials have shown the clinical.

Spinal Cord Stimulation for Heart Failure Stuart P. Rosenberg, M.S. Senior Manager, Neuromodulation Research Implantable Electronic Systems Division St.

Devices and the older patient with syncope Michael Gammage, Reader in Cardiovascular Medicine MHRA Committee for Safety of Devices.

 Copy: few empirical studies compared to other treatments  Eysenck- reviewed 2 studies, incorporating waiting list controls, which showed that 66% of.

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

Camm J, et al. On Behalf of The SHIFT Gothenburg, Cardiac safety of selective heart rate reduction with Ivabradine in chronic heart failure. Poster, Heart.

Impact of ISDN-hydralazine on mortality and morbidity of African-American patients with Heart Failure A-Heft Trial Presented at American Heart Association.

S. HUNT Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

Activity in Heart Failure

Risk of bolus thrombolytics Shamir Mehta, MD Director, Coronary Care Unit McMaster University Medical Center Hamilton, Ontario Paul Armstrong, MD Professor.

Natural History of Heart Failure

New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.

Increased Patient Device Concerns But Not General Anxiety in Patients with a Secondary Indication for the ICD Susanne S. Pedersen, Professor of Cardiac.

The CHART-2 Study (The Chronic Heart Failure Analysis and Registry in the Tohoku District 2) Source Shiba N, Nochioka K, Miura M, et al. Trend of westernization.

Biomarkers that “guide” therapy

DIAGNOSIS No symptoms = no heart failure. DIAGNOSIS No symptoms = no heart failure.

Creighton University College of Nursing, Omaha, NE

Revascularization in Patients With Left Ventricular Dysfunction:

Colleen K. McIlvennan, DNP, ANP

Department of Cardiology Bern University Hospital

Forecasting the Impact of Heart Failure in the United States

Atrial Fibrillation and Mortality in Heart FailureClinical Perspective

Treatment of Left Ventricular Assist Device Thrombosis With Extended Catheter-Directed Intraventricular Thrombolytic Therapy by Thenappan Thenappan, Allen.

EMPHASIS-HF Extended Follow-up

Arterial Stiffness, Central Pressures, and Incident Hospitalized Heart Failure in the Chronic Renal Insufficiency Cohort StudyCLINICAL PERSPECTIVE by Julio.

Effects of Mineralocorticoid Receptor Antagonists on the Risk of Sudden Cardiac Death in Patients With Left Ventricular Systolic DysfunctionClinical Perspective.

Comparison of in‐hospital outcomes, including (A) technical failure, (B) postprocedural complications, (C) postprocedural hospital length of stay, and.

DO NOT DELAY TAKING CARE OF YOUR HEART AND LUNG PROBLEMS Let our team of experts take care of you.

AGA KHAN UNIVERSITY HOSPITAL HEALTH SCREENING TESTING PANEL PACKAGES

AGA KHAN UNIVERSITY HOSPITAL INTERNATIONAL OVERDOSE AWARENESS DAY 2018.

Clyde W. Yancy et al. JACC 2017;70:

STEMI-INITIAL PRESENTATION TIMING 2013 ACC/AHA GUIDELINES

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

Heart Failure Prevention: Mission Impossible?

INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.

PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg.

Zuzana Motovska et al. JACC 2018;71:

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

ATMOSPHERE Trial design: Patients with symptomatic heart failure were randomized in a 1:1:1 fashion to either aliskiren 300 mg once daily, enalapril 5.

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

Nat. Rev. Cardiol. doi: /nrcardio

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

CAD and HF Often Coexist

Anaerobic threshold responder analysis

CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.

Peter E. Carson et al. JCHF 2015;3:

Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.

TRUE-AHF Trial design: Patients with acute decompensated heart failure were randomized in a 1:1 fashion to either early ularitide infusion (within 12 hours)

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Associations between type of MI and incident HF

Cost-effectiveness plane for all PARTNER-B vs all ADVANCE and all PARTNER vs ADVANCE high risk comparisons with ICERs from five studies; dashed line represents.

Rick A. Nishimura et al. JACC 2017;70:

Recurrence of HF hospitalization Total-time approach

Jeffrey Senfield et al. JACEP 2017;3:

Case Study #1. Management of Heart Failure With Comorbidities: Challenging Cases for the Cardiologist.

Comparison of heart failure admissions rates per annum (recorded hospital admissions/ population at risk) in western developed countries 1978 to.

Presentation transcript:

Dr M. Abubakr Shaikh The Aga Khan University Hospital, Karachi HEART FAILURE GUIDELINES: A COMPARISON

HEART FAILURE GUIDELINES Eur Heart J 1995;16: JACC 2001;38: / Circ 2001;104: Circ 2005;112: J Card Failure 2006;12:e1-e122

CONCLUSIONS HF guidelines have evolved to promote aggressive medical therapy Controversy exists regarding indications of device therapy despite clear scientific evidence, due to other factors For better efficacy, ECG criteria should be substituted by echo and EP criteria for device therapy

Adams KF, Lindenfeld J, et al. HFSA 2006 Comprehensive Heart Failure Guideline. J Card Fail 2006;12:e1-e122.